2 Chlorodeoxyadenosine

From Anvita Health Wiki

Contents 1 Introduction 2 Indications 3 Dosage 4 Monitor 5 Adverse-effects 6 More General Terms 7 Internet Database 8 References

Introduction

• Alias: cladribine. Tradename: Leustatin.

Indications

• hairy cell leukemia
• B-cell chronic lymphocytic leukemia resistant to fludarabine
• follicular lymphoma

Dosage

• Adults: 0.09-0.1 mg/kg/day continuous infusion for 7 consecutive days
• prophylactic allopurinol should be considered because of potential for tumor lysis syndrome

• Vials: 1 mg/mL, 10 mL.

Monitor

• CBC especially during 1st 4-8 weeks post-treatment

Adverse-effects

• common (> 10%)

• fatigue
• rash
• injection site reactions
• headache
• bone marrow suppression

• platelet counts decrease in 1st 1 weeks & normalize by day 12
• neutrophil count declines but normalize by week 5
• hemoglobin declines but normalizes by week 6

• fever

• 66% within 1st month
• < 33% of febrile events associated with documented infection

• gastrointestinal

• decreased appetite
• nausea/vomiting
• diarrhea

• less common (1-10%)

• edema, tachycardia, pruritis, pain, erythema, dizziness, insomnia, myalgia/ arthralgia, constipation, abdominal pain, chills, asthenia, diaphoresis, malaise, trunk pain

More General Terms

• antineoplastic agent (chemotherapeutic agent)
• purine analog

Internet Database

PubChem: 20279
PubChem: 1546

References

1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
2. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 529
3. Department of Veterans Affairs, VA National Formulary

2-chlorodeoxyadenosine (2-CdA) [cladribine] (Leustatin)